Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Inherited quantitative (type I) or qualitative (type II) antithrombin deficiency (ATD) due to mutations in the SERPINC1 gene is a well-known risk factor for venous thromboembolism.
|
28300866 |
2017 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We investigated the VTE risk associated with SNPs in the GP6 (rs1613662), SERPINC1 (rs2227589), F11 (rs2036914 and rs2289252), FGG (rs2066865), and F12 (rs1801020) genes.
|
23150947 |
2013 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The major clinical manifestations of ATIII deficiency are young age at onset, idiopathic thrombosis, family history, and recurrent venous thromboembolism.
|
2679068 |
1989 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The inherited thrombophilias--deficiencies of protein C, protein S, and antithrombin III--and the prothrombotic polymorphisms factor V G1691A and factor II G20210A predispose patients toward venous thromboembolism (VTE).
|
10073951 |
1999 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We performed a meta-analysis with trial sequential analysis to investigate the associations between the endothelial cell-activated protein C receptor (EPCR) rs9574, F11 rs2289252, F11 rs2036914, FGG rs2066865, FGG rs1049636, CYP4V2 rs13146272, SERPINC1 rs2227589, and GP6 rs1613662 polymorphisms with the risk of VTE.
|
28353616 |
2017 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Inherited deficiency of antithrombin III is a well recognised risk factor for the early development of venous thromboembolism.
|
7937056 |
1994 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Four members of an Italian family (two with histories of venous thromboembolism) had a qualitative defect of antithrombin III reflected by normal antigen concentrations and half-normal antithrombin activity with or without heparin.
|
3563966 |
1986 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Mutations in SERPINC1 and PROC lead to deficiency or dysfunction of the two proteins, which could result in venous thromboembolism (VTE).
|
28861852 |
2018 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
This study demonstrated that different types of SERPINC1 mutations may play different roles in the development of VTE and should be considered in the prevention of VTE.
|
27863268 |
2016 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We investigated SERPINC1 defects in Japanese patients with congenital AT deficiency who developed venous thromboembolism or had a family history of deep vein thrombosis.
|
31030036 |
2019 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
After adjustment for other inherited causes of thrombophilia (deficiency of antithrombin III, protein C or S, factor V Leiden) the overall risk for VTE associated with the prothrombin polymorphism was 3.4 times higher than in the controls (95% CI, 2.0 to 5.8).
|
12551828 |
2003 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
These defects are responsible for only a moderate increase of venous thromboembolism (VTE) risk compared with strong thrombophilias (antithrombin III, protein C and protein S deficiencies and homozygous forms of factor V Leiden and G20210A prothrombin mutation).
|
23026651 |
2012 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
The effect of chlorotrianisene as postpartum lactation suppression on blood coagulation factors.
|
453287 |
1979 |